Walgreens is the highest-risk major pharmacy NNN tenant after Sycamore Partners’ $10B take-private (Aug 2025, 70.9% debt-financed) split the company into five operating entities and accelerated a 1,200-store closure timeline. Cap rates currently span 6.50-8.00%+ — among the widest pharmacy caps available — reflecting credit migration risk. Verify which post-split entity guarantees your lease.

Pros:

• Long primary terms (20-25 years) with options
• Real estate scarcity in pharmacy NNN — Rite Aid liquidated, CVS BBB only IG peer
• Standalone freestanding pads in primary trade areas remain defensible
• Wider cap rates (6.50-8.00%+) create alpha for selective NNN buyers

Cons:

• Sycamore $10B take-private Aug 2025 — 70.9% debt financed per DEFM14A
• 1,200-store closure plan accelerating under Sycamore ownership
• S&P and Moody’s withdrew ratings post-take-private
• Senator Warren + PESP flagging bankruptcy risk over 3-5 year hold

Walgreens Boots Alliance became Sycamore Partners’ largest healthcare bet on August 28, 2025 when the private equity firm closed its $10 billion take-private of the legacy public pharmacy operator. The deal — financed 70.9% with debt per the DEFM14A — is among the most leveraged buyouts in retail history. As part of the take-private, the legacy company has been split into five separate operating entities: Walgreens (US retail), Boots (UK/European pharmacy), Shields Health Solutions (specialty pharmacy services), CareCentrix (post-acute care), and VillageMD (primary care platform). Mike Motz, former Staples US Retail CEO and Sycamore portfolio executive, was named Walgreens CEO.

Walgreens is now the highest-risk major pharmacy NNN tenant available. S&P and Moody’s withdrew their long-term ratings (previously BB- and Ba2, respectively) at the deal close. Senator Elizabeth Warren wrote formally to Sycamore Partners in April 2025 warning that the leveraged buyout ‘may lead to pharmacy closures, lost jobs in Massachusetts, and limit access to medication.’ The Private Equity Stakeholder Project has flagged Sycamore’s track record (70% of Q1 2025 large corporate bankruptcies were PE-owned) as a meaningful 3-5 year hold-period risk. Standalone freestanding pads with strong demographics and 15+ years remaining are still defensible product, but the credit-migration story is material and underwriters should price accordingly.

The closure program is real and accelerating. Walgreens announced a 1,200-store closure plan in October 2024 over three years, and Sycamore has pulled the timeline forward. In February 2026, the company announced 628 corporate position eliminations at the Deerfield, Illinois headquarters and the Houston logistics center. The central-fill micro-fulfillment model — 11 distribution centers serving 4,500+ stores and targeting 6,000+ — is structurally enabling further pharmacy consolidation by removing in-store pharmacist labor from individual stores. For NNN landlords: density-overlap properties are at highest risk; well-located freestanding standalone boxes in primary trade areas with strong demographics continue to be retained.

Walgreens does not franchise. Every NNN lease is corporate-guaranteed — but the post-split entity structure means landlords must verify which of the five operating companies is the actual guarantor on their lease. In most cases this will be the Walgreens (US retail) entity. The five-entity structure also raises the prospect of further asset sales: Boots (UK) sale discussions have been ongoing in 2025-2026, and Shields, VillageMD, and CareCentrix have all been considered for divestiture. Each potential transaction creates credit-migration uncertainty for the surviving Walgreens US retail entity.

Typical Walgreens NNN leases run 20-25 year primary terms with flat rent through the primary term and bumps in option periods on standalone 14,500 SF buildings sited on 1.5-1.8 acre pads. National average rent runs $300,000-$450,000 on legacy 20-year standalone NNN.  Newer 20-year ground leases trade tighter. For NNN buyers willing to underwrite the credit-migration scenario, the wider cap creates alpha that the surviving CVS-only pharmacy comparable does not offer.